Do analysts rate INKT or FTFT?

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 191.67%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor INKT or FTFT?

In the previous week, Future FinTech Group had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 5 mentions for Future FinTech Group and 3 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.88 beat Future FinTech Group's score of 0.57 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Future FinTech Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor INKT or KROS?

In the previous week, Keros Therapeutics had 5 more articles in the media than MiNK Therapeutics. MarketBeat recorded 8 mentions for Keros Therapeutics and 3 mentions for MiNK Therapeutics. Keros Therapeutics' average media sentiment score of 1.23 beat MiNK Therapeutics' score of 0.88 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, INKT or ABOS?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A

Is INKT or ABOS more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% Acumen Pharmaceuticals N/A -136.27% -81.64%

Does the media favor INKT or ABOS?

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 3 articles in the media. MiNK Therapeutics' average media sentiment score of 0.88 beat Acumen Pharmaceuticals' score of 0.63 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, PEPG or INKT?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.31 N/A MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A

Is PEPG or INKT more profitable?

MiNK Therapeutics' return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -51.01% -43.49% MiNK Therapeutics N/A N/A -92.37%

Does the media prefer PEPG or INKT?

In the previous week, PepGen had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 5 mentions for PepGen and 3 mentions for MiNK Therapeutics. PepGen's average media sentiment score of 0.94 beat MiNK Therapeutics' score of 0.88 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to INKT or PRQR?

In the previous week, ProQR Therapeutics had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 4 mentions for ProQR Therapeutics and 3 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.88 beat ProQR Therapeutics' score of 0.64 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MiNK Therapeutics (INKT) Competitors

$12.00 -0.13 (-1.07%)

Closing price 09/11/2026 03:49 PM Eastern

Extended Trading

$12.60 +0.60 (+4.98%)

As of 09/11/2026 07:55 PM Eastern

Compare

INKT vs. FTFT, KROS, ABOS, PEPG, and PRQR

Should you buy MiNK Therapeutics stock or one of its competitors? MiNK Therapeutics's main competitors and comparable companies include Future FinTech Group (FTFT), Keros Therapeutics (KROS), Acumen Pharmaceuticals (ABOS), PepGen (PEPG), and ProQR Therapeutics (PRQR). Companies are selected based on similarities in market, industry, and size.

How does MiNK Therapeutics compare to Future FinTech Group?

MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

In the previous week, Future FinTech Group had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 5 mentions for Future FinTech Group and 3 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.88 beat Future FinTech Group's score of 0.57 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Future FinTech Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 1.5% of Future FinTech Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MiNK Therapeutics presently has a consensus price target of $35.00, suggesting a potential upside of 191.67%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Future FinTech Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -157.53%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Future FinTech Group	-157.53%	-12.22%	-10.08%

MiNK Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Future FinTech Group has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Future FinTech Group	$3.83M	7.05	-$4.62M	-$30.16	N/A

Summary

MiNK Therapeutics beats Future FinTech Group on 9 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Keros Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Keros Therapeutics (NASDAQ:KROS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

MiNK Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. MiNK Therapeutics' return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Keros Therapeutics	-256.60%	-21.40%	-19.79%

Keros Therapeutics has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Keros Therapeutics	$244.06M	0.90	$87.01M	-$3.70	N/A

MiNK Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

MiNK Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 191.67%. Keros Therapeutics has a consensus target price of $20.50, suggesting a potential upside of 85.02%. Given MiNK Therapeutics' higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Keros Therapeutics had 5 more articles in the media than MiNK Therapeutics. MarketBeat recorded 8 mentions for Keros Therapeutics and 3 mentions for MiNK Therapeutics. Keros Therapeutics' average media sentiment score of 1.23 beat MiNK Therapeutics' score of 0.88 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Keros Therapeutics beats MiNK Therapeutics on 10 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Acumen Pharmaceuticals?

MiNK Therapeutics (NASDAQ:INKT) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

In the previous week, MiNK Therapeutics and MiNK Therapeutics both had 3 articles in the media. MiNK Therapeutics' average media sentiment score of 0.88 beat Acumen Pharmaceuticals' score of 0.63 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MiNK Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 191.67%. Acumen Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 173.97%. Given MiNK Therapeutics' higher probable upside, equities research analysts plainly believe MiNK Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

MiNK Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.37, suggesting that its stock price is 63% less volatile than the broader market.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

MiNK Therapeutics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

Summary

MiNK Therapeutics and Acumen Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does MiNK Therapeutics compare to PepGen?

PepGen (NASDAQ:PEPG) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

MiNK Therapeutics' return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-51.01%	-43.49%
MiNK Therapeutics	N/A	N/A	-92.37%

PepGen has a beta of 1.97, suggesting that its share price is 97% more volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

58.0% of PepGen shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 20.4% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.31	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A

In the previous week, PepGen had 2 more articles in the media than MiNK Therapeutics. MarketBeat recorded 5 mentions for PepGen and 3 mentions for MiNK Therapeutics. PepGen's average media sentiment score of 0.94 beat MiNK Therapeutics' score of 0.88 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PepGen presently has a consensus target price of $11.50, indicating a potential upside of 285.91%. MiNK Therapeutics has a consensus target price of $35.00, indicating a potential upside of 191.67%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

PepGen beats MiNK Therapeutics on 10 of the 13 factors compared between the two stocks.

How does MiNK Therapeutics compare to ProQR Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MiNK Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

MiNK Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. MiNK Therapeutics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

MiNK Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
ProQR Therapeutics	$17.99M	10.89	-$47.73M	-$0.46	N/A

MiNK Therapeutics currently has a consensus price target of $35.00, suggesting a potential upside of 191.67%. ProQR Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 303.23%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, ProQR Therapeutics had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 4 mentions for ProQR Therapeutics and 3 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.88 beat ProQR Therapeutics' score of 0.64 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ProQR Therapeutics beats MiNK Therapeutics on 9 of the 15 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INKT vs. The Competition

Export

Metric	MiNK Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$61.24M	$3.86B	$7.16B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-5.00	14.18	274.94	25.33
Price / Sales	N/A	1,378.88	633.80	90.72
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	-3.96	15.12	10.33	6.21
Net Income	-$12.49M	-$22.86M	$3.50B	$358.54M
7 Day Performance	3.09%	-4.34%	-3.32%	-2.35%
1 Month Performance	9.09%	0.54%	-0.53%	-3.23%
1 Year Performance	-16.67%	40.74%	23.51%	8.79%

MiNK Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INKT MiNK Therapeutics	2.6902 of 5 stars	$12.00 -1.1%	$35.00 +191.7%	-16.7%	$61.24M	N/A	N/A	30	High Trading Volume
FTFT Future FinTech Group	0.4265 of 5 stars	$1.63 -1.2%	N/A	-98.6%	$15.47M	$3.83M	N/A	70	Short Interest Increase Gap Up
KROS Keros Therapeutics	3.6732 of 5 stars	$11.32 +1.9%	$20.50 +81.1%	-29.2%	$224.44M	$15.01M	N/A	100	Positive News Buyback Announcement
ABOS Acumen Pharmaceuticals	2.312 of 5 stars	$3.18 +2.9%	$8.00 +151.6%	+121.2%	$223.46M	N/A	N/A	20	News Coverage Gap Up
PEPG PepGen	2.711 of 5 stars	$3.11 -2.2%	$11.50 +269.8%	+101.4%	$220.24M	N/A	N/A	30	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INKT) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, KROS, ABOS, PEPG, and PRQR

How does MiNK Therapeutics compare to Future FinTech Group?

Summary

How does MiNK Therapeutics compare to Keros Therapeutics?

Summary

How does MiNK Therapeutics compare to Acumen Pharmaceuticals?

Summary

How does MiNK Therapeutics compare to PepGen?

Summary

How does MiNK Therapeutics compare to ProQR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, KROS, ABOS, PEPG, and PRQR

How does MiNK Therapeutics compare to Future FinTech Group?

Does the media favor INKT or FTFT?

Do institutionals and insiders hold more shares of INKT or FTFT?

Do analysts rate INKT or FTFT?

Is INKT or FTFT more profitable?

Which has more risk and volatility, INKT or FTFT?

Which has stronger earnings and valuation, INKT or FTFT?

Summary

How does MiNK Therapeutics compare to Keros Therapeutics?

Is INKT or KROS more profitable?

Which has better valuation & earnings, INKT or KROS?

Which has more risk and volatility, INKT or KROS?

Do analysts prefer INKT or KROS?

Do insiders and institutionals have more ownership in INKT or KROS?

Does the media favor INKT or KROS?

Summary

How does MiNK Therapeutics compare to Acumen Pharmaceuticals?

Does the media favor INKT or ABOS?

Do analysts prefer INKT or ABOS?

Which has more risk and volatility, INKT or ABOS?

Do insiders and institutionals have more ownership in INKT or ABOS?

Which has better valuation & earnings, INKT or ABOS?

Is INKT or ABOS more profitable?

Summary

How does MiNK Therapeutics compare to PepGen?

Is PEPG or INKT more profitable?

Which has more risk & volatility, PEPG or INKT?

Do insiders & institutionals hold more shares of PEPG or INKT?

Which has stronger earnings and valuation, PEPG or INKT?

Does the media prefer PEPG or INKT?

Do analysts recommend PEPG or INKT?

Summary

How does MiNK Therapeutics compare to ProQR Therapeutics?

Do institutionals & insiders hold more shares of INKT or PRQR?

Which has more risk and volatility, INKT or PRQR?

Is INKT or PRQR more profitable?

Which has higher valuation & earnings, INKT or PRQR?

Do analysts prefer INKT or PRQR?

Does the media refer more to INKT or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools